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INTRODUCTION
Research and its associated publications have had a considerable impact on the care andmonitoring
of the patients since evidence-based medicine became standard for modern medicine during the
1990s (1). Peer-reviewing is a fundamental component of scientific publication. The peer-review
process first includes an evaluation of the quality and interest in the paper for the reader of the
journal by the editor who, if he or she considers the article to be of interest, sends it to the external
reviewers (2). If the paper is found to be interesting and of sufficient quality, the reviewers ask
questions and make comments to which the researcher must respond in a rebuttal letter. If the
answers are satisfactory, the article can be published. This is a time-consuming process, typically
lasting months, and authors complain about the review time, which has been relatively stable since
the 1980s (3).
THE EVOLUTION OF SCIENTIFIC PUBLICATIONS
In previous decades, the world of scientific publishing has changed enormously with an explosion
in the number of publishers and journals. Therefore, there has been an exponential increase in the
number of scientific papers published (4). The way that information is distributed has also changed,
with an increasing number of journals being available in open access format. In this model, the cost
of the publication is paid by the authors, and the manuscript is then freely available once accepted
for publication. Traditionally there is no cost to publish the paper; the publishers sell articles or
subscription systems through university libraries.
There are pros and cons to open access format, which are not going to be discussed here as they
are outside the scope of this paper. However, from an individual’s point of view, this is an interesting
evolution, enabling readers to keep up to date with scientific research without having to take out
a subscription.
In recent years, another phenomenon that has been developing is also having an increasing
impact on research: preprints. The preprint is a version of a scientific paper that precedes the
peer review process, and the article is freely available without any form of control by the editor
or reviewers. Furthermore, most preprints receive a digital object identifier (DOI). Authors can,
therefore, reference them in their bibliography or grant applications. Subsequent revisions are time-
stamped, and anyone can read and comment on the paper. This collaborative aspect is often put
forward by the proponents of this model.
Initially developed in the field of physics and economy (e.g., arXiv, RePEc), this practice is now
spreading to themedical world and other domains of research. Preprints were the fastest-growing of
all types of research output (around 30%) in 2016–2018, compared with article growth of 2–3% (5).
Although preprint publishers have a legal obligation to indicate, in the article, that it is a draft
that has not been peer-reviewed, the recent COVID-19 pandemic has highlighted the ambiguity
raised by this practice in medicine.
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In this paper, we discuss the impact of preprints on the
general population, the media, and research more generally from
the researchers’ and publishers’ points of view. We also present
different solutions to improve the current publication model
that ensure the authorship of innovation while guaranteeing the
quality and accuracy of publications.
PUBLIC IMPACT
Before going further, it must be said that the COVID-19
pandemic is an exceptional situation that was unprecedented for
the general population at large. This crisis has highlighted the role
of dissemination of research to the general public but has also
demonstrated some limitations of the current research model or,
at least, the dissemination of the results.
With maximum media coverage, and in the absence of
effective treatment, journalists were on the lookout for the
slightest piece of information, verified or not. The information
contained in preprints has been spread to the general public
by both official and unofficial media, without reference to their
distinction from peer-reviewed papers. Preprints and media are
not the only ones to blame as numerous publication scandals
have erupted during this crisis which, in the context of fake news
and misinformation, has certainly not helped the recognition
of research (6) and the confidence in research process by the
public (7).
In this context, the public has been confused by the mass
of information available. We can cite, as examples, some of the
most striking cases of this crisis: a genomic study of the virus
carried out by an Indian team who had discovered similarities
with HIV, opening the door to a conspiracy theory, which was
then withdrawn by the authors after significant methodological
errors were identified by the readers of the preprint (8). The
most famous examples are the publication scandal related to the
danger of hydroxychloroquine that were detailed in the Lancet
(9) and the New England Journal of Medicine (10).
It should be pointed out, however, that two of the three
examples given above-involved articles published in peer-
reviewed and high-impact journals—proof that the review
process is not perfect and does not always guarantee the accuracy
of the results (11). During the COVID-19 crisis, due to political
pressure for fast publication, most of the journals implemented
a fast-track review process (i.e., a shorter period of time to
review the paper). It is challenging for the reviewers to check
the plausibility and quality of the data and statistics, which could
explain the scandals and the retractions.
THE RESEARCHER POINT OF VIEW
Modern research can be summarized by two words: novelty and
innovation (12). Scientists promote preprints because they enable
researchers to claim priority (i.e., intellectual property) and make
their findings available more quickly (13). Another advantage
of preprints was demonstrated by a recent study showing that
articles with a preprint have, on average, a 49% higher Altmetric
Attention Score and 36% more citations than articles without
a preprint (14). Since most of preprints have a DOI, some
researchers use preprints to artificially boost their bibliography
for grant applications or promotions.
Innovation is, of course, the raison d’être of scientific research.
That being said, by promoting innovation above all, there is a
great risk that the authors will want to rush their studies and draw
incomplete or incorrect conclusions (15). This phenomenon was
accentuated during the crisis, during which intermediate and
incomplete results of clinical studies were published as a result of
political pressure. The authors also wanted to make themselves
known in order to submit special projects related to the COVID.
On the other hand, an essential aspect of the research is the
protection of novelty using patents. Inventions can be patented if
they are novel, non-obvious, and useful (16). When an invention
is publicly disclosed, it enters into state of the art. Consequently,
no one will be able to patent the same invention as the novelty
requirement has been impeded (17). Prior art, the material
publicly available prior to the filing date of the patent, includes
all the different sources of publications, it therefore also includes
the preprints. This can have a substantial negative effect on
the translation of an invention into an innovation that has the
potential to reach the patient. Indeed, if an invention cannot
be patented, it loses the interest of the private companies.
Even if researchers are less comfortable with writing patents,
they should therefore first patent innovation before publishing
anything related to this, whatever the publication is peer-
reviewed, preprint, or event conference presentation, to foster
innovation (18).
Paradoxically, while the number of published papers is
growing exponentially, it seems that it has become more and
more challenging to reach a consensus within the scientific
community, and the results of published studies are difficult
to reproduce. Some authors argue, therefore, that there is
currently a reproducibility crisis as most scientists have failed to
reproduce the results of published papers (19, 20). With the rapid
publication of incomplete and unverified results, preprints are
contributing to a significant increase in the quantity of research,
often difficult to replicate due to vague or incomplete description
of the protocol and the low quality of the results.
These findings are particularly compelling in the field of
healthcare, where treatment decisions are made based on the
results of clinical studies (21), especially since results of preprints
are now included in some meta-analyses (22). Replicated studies
should not be undervalued by editors and should receive the
attention they deserved to solve this reproducibility crisis (23).
Another useful way to protect novelty and innovation is to
make data available for other researchers (24). A growing number
of journals require authors to share data by depositing them in a
repository when submitting their manuscripts. This is beneficial
not only in ensuring the correct analysis and interpretation of
the results but also to ensure that the data are used to their
fullest potential for improving individual and public health (25).
Some ethical questions of sharing issues can, however, arise—
especially—when private companies are involved in the research
(e.g., commercial use of personal data) (26). Therefore, this
practice needs to be well-supervised, and the data must be
fully protected.
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FROM A PUBLISHER PERSPECTIVE
For the publishers, three aspects of preprints need to be
considered: the content, the repository (i.e., publication and
distribution), and the financial impact.
Concerning the content, some journals, such as the New
England Journal of Medicine or Science, view draft preprints
as prior publications (prior art, see above) and, thus, they are
unacceptable as new manuscript submissions (5).
Some publishers (e.g., MDPI, JMIR Publications) have their
own preprint repository, allowing for better synchronization
between the preprint and final versions of the paper. Ideally,
preprints should be removed once the article has been accepted
or rejected.
Concerning the financial impact, we noticed that preprints
often stay online, which represents a potential loss of income
for the publishers and can be confusing if the final version of
the published paper contains substantial changes compared with
the first (preprint) version. On the other hand, we have seen that
papers with a preprint have more citations that papers without
preprint (14), which represents an increase in visibility, and
therefore potentially in the revenues generated.
CONCLUSION AND CALL FOR ACTION
As a scientist, the increasingly widespread use of preprints is an
excellent opportunity to question the current limits of the peer
review process. Publication scandals are not uncommon, even in
high impact factor journals (although this can be biased because
those journals are more widely read and analyzed, so we cannot
confirm that scandals are more common specifically for top
journals) (27). Solutions to increase the quality of peer-reviewing
have been proposed: single vs. double-blind peer review (28) or
open peer review (29).
Between financial interests, on the one hand, and personal
stakes (i.e., the need to publish) on the other, the publishing
world is a key factor in research. It would, therefore, be utopian
to promote the end of preprints, especially since we have seen
that it increases the visibility and citations of papers, which is
good for both researchers and publishers. Rather than abolishing
preprints, we are instead advocating a stricter framework for this
practice, and better information to the public and the media on
the differences between preprints and peer-reviewed papers.
We suggest that preprints are published only once the
manuscript is under review in one journal, indicating that it
has at least been screened and checked by an editor, and that
it is indicated in the preprint in which journal the paper has
been submitted.
By doing so, the authors retain the advantage of the preprint—
speed of publication and previous tracing in cases of conflict (i.e.,
intellectual property but authors should be aware that preprints
are part of the prior art)—as well as saving time and money by
avoiding duplication, with at least a first control by the journal
and the editor.
After the review process, the preprint should be removed
in the case of acceptance in order to leave only the final
version online. Scientific literature is already so prolific that it is
necessary to avoid having to take duplicates between preprints
and published papers into account. In the case of rejection,
the preprint should also be withdrawn, since the reviewers felt
that the paper could not be published for various reasons (e.g.,
methodological issues).
Finally, we do not think that preprints should receive a DOI,
or at least, that it should not be used for grant submission. It is
certain that this aspect of preprints leads to the most abuse and
ultimately undermines the quality and reputation of research.
By applying these few recommendations, the positive aspects
of preprints are preserved for the authors, and the quality of the
published papers will be preserved without creating ambiguity in
the general public.
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